Robotic-assisted, laparoscopic, and open radical cystectomy: surgical data of 1400 patients from The Italian Radical Cystectomy Registry on intraoperative outcomes.
bladder cancer
intraoperative outcomes
multicenter registry
radical cystectomy
robotic-assisted
Journal
Central European journal of urology
ISSN: 2080-4806
Titre abrégé: Cent European J Urol
Pays: Poland
ID NLM: 101587101
Informations de publication
Date de publication:
2022
2022
Historique:
received:
02
12
2021
revised:
27
02
2022
accepted:
04
04
2022
entrez:
8
8
2022
pubmed:
9
8
2022
medline:
9
8
2022
Statut:
ppublish
Résumé
The Italian Radical Cystectomy Registry (Registro Italiano Cistectomie - RIC) aimed to analyse outcomes of a multicenter series of patients treated with radical cystectomy (RC) for bladder cancer. An observational, prospective, multicenter, cohort study was performed to collect data from RC and urinary diversion via open (ORC), laparoscopic (LRC), or robotic-assisted (RARC) techniques performed in 28 Italian Urological Departments. The enrolment was planned from January 2017 to June 2020 (goal: 1000 patients), with a total of 1425 patients included. Chi-square and t-tests were used for categorical and continuous variables. All tests were 2-sided, with a significance level set at p <0.05. Overall median operative-time was longer in RARCs (390 minutes, IQR 335-465) than ORCs (250, 217-309) and LRCs (292, 228-350) (p <0.001). Lymph node dissection (LND) was performed more frequently in RARCs (97.1%) and LRCs (93.5%) than ORCs (85.6%) (p <0.001), with extended-LND performed 2-fold more frequently in RARCs (61.6%) (p <0.001). The neobladder rate was significantly higher (more than one-half) in RARCs. The median estimated blood loss (EBL) rate was lower in RARCs (250 ml, 165-400) than LRCs (330, 200-600) and ORCs (400, 250-600) (p <0.001), with intraoperative blood transfusion rates of 11.4%, 21.7% and 35.6%, respectively (p <0.001). The conversion to open rate was slightly higher in RARCs (6.8%) than LRCs (4.3%). Intraoperative complications occurred in 1.3% of cases without statistically significant differences among the approaches. Data from the RIC confirmed the need to collect as much data as possible in a multicenter manner. RARCs proves to be feasible with perioperative complication rates that do not differ from the other approaches.
Identifiants
pubmed: 35937656
doi: 10.5173/ceju.2022.0284
pii: 0284
pmc: PMC9326698
doi:
Types de publication
Journal Article
Langues
eng
Pagination
135-144Informations de copyright
Copyright by Polish Urological Association.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
BMC Cancer. 2021 Jan 11;21(1):51
pubmed: 33430820
J Endourol. 2016 Jul;30(7):783-91
pubmed: 27055782
Surg Technol Int. 2019 May 15;34:302-309
pubmed: 31037718
Eur Urol. 2015 Jun;67(6):1042-1050
pubmed: 25496767
World J Urol. 2021 Mar;39(3):803-812
pubmed: 32419055
Eur Urol. 2014 Jan;65(1):193-200
pubmed: 24018019
Trials. 2009 Feb 06;10:9
pubmed: 19200379
Urol Oncol. 2014 Nov;32(8):1184-90
pubmed: 25027683
Cochrane Database Syst Rev. 2019 Apr 24;4:CD011903
pubmed: 31016718
Cancer. 2008 Jun;112(11):2401-8
pubmed: 18383515
Lancet. 2018 Jun 23;391(10139):2525-2536
pubmed: 29976469
Cancer. 2006 Nov 15;107(10):2368-74
pubmed: 17041887
J Urol. 2011 Oct;186(4):1261-8
pubmed: 21849183
BJU Int. 2014 May;113(5b):E39-48
pubmed: 24053715
BJU Int. 2015 Jun;115(6):937-45
pubmed: 25294421
J Urol. 2019 Apr;201(4):715-720
pubmed: 30321551
Eur Urol. 2015 Mar;67(3):376-401
pubmed: 25560798
Investig Clin Urol. 2016 Jun;57 Suppl 1:S36-43
pubmed: 27326405
Eur Urol Focus. 2019 Nov;5(6):1058-1065
pubmed: 29779842
BMC Cancer. 2018 Sep 3;18(1):861
pubmed: 30176832
Minerva Urol Nefrol. 2018 Apr;70(2):193-201
pubmed: 29161805
Urol Oncol. 2016 Jun;34(6):257.e1-9
pubmed: 26968561
Eur Urol. 2014 Dec;66(6):1065-77
pubmed: 25074764
Eur Urol. 2015 Mar;67(3):363-75
pubmed: 25582930
World J Surg Oncol. 2019 Dec 21;17(1):225
pubmed: 31864368
PLoS One. 2014 May 16;9(5):e95667
pubmed: 24835573
Eur Urol. 2021 Apr;79(4):480-488
pubmed: 33419683
Eur Urol. 2019 Apr;75(4):604-611
pubmed: 30337060
Eur Urol. 2021 Jan;79(1):82-104
pubmed: 32360052